Insider Selling: Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Sells $44,920.00 in Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 1,123 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total value of $44,920.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Jeffrey Dierks also recently made the following trade(s):

• On Wednesday, January 15th, Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock. The shares were sold at an average price of $37.01, for a total value of $388,864.07.
• On Tuesday, October 29th, Jeffrey Dierks sold 21,496 shares of Harmony Biosciences stock. The shares were sold at an average price of $40.47, for a total value of $869,943.12.

Harmony Biosciences Stock Down 1.7 %

Shares of HRMY stock opened at $38.01 on Friday. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61. The stock has a market cap of $2.17 billion, a P/E ratio of 18.01, a P/E/G ratio of 0.53 and a beta of 0.78. The company has a 50 day simple moving average of $34.66 and a two-hundred day simple moving average of $35.05.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.64 by $0.15. The firm had revenue of $186.00 million during the quarter, compared to analyst estimates of $184.07 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. Harmony Biosciences’s revenue was up 16.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.63 EPS. On average, research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Envestnet Asset Management Inc. raised its stake in Harmony Biosciences by 19.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 61,397 shares of the company’s stock worth $1,852,000 after acquiring an additional 10,167 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Harmony Biosciences by 13.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock valued at $28,871,000 after purchasing an additional 112,197 shares during the period. Hsbc Holdings PLC lifted its stake in shares of Harmony Biosciences by 208.1% during the 2nd quarter. Hsbc Holdings PLC now owns 23,800 shares of the company’s stock valued at $731,000 after buying an additional 16,076 shares in the last quarter. Profund Advisors LLC boosted its holdings in Harmony Biosciences by 11.1% in the 2nd quarter. Profund Advisors LLC now owns 7,557 shares of the company’s stock worth $228,000 after buying an additional 758 shares during the period. Finally, Public Sector Pension Investment Board boosted its holdings in Harmony Biosciences by 2.9% in the 2nd quarter. Public Sector Pension Investment Board now owns 70,020 shares of the company’s stock worth $2,113,000 after buying an additional 1,955 shares during the period. 86.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on HRMY shares. Raymond James reissued an “outperform” rating and set a $40.00 price objective on shares of Harmony Biosciences in a research report on Thursday, October 10th. Needham & Company LLC reissued a “buy” rating and set a $52.00 price target on shares of Harmony Biosciences in a research report on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Harmony Biosciences in a research report on Thursday, January 16th. Oppenheimer reissued an “outperform” rating and issued a $59.00 target price (up previously from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Finally, Cantor Fitzgerald upped their price target on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Harmony Biosciences presently has an average rating of “Buy” and an average target price of $55.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.